BioLineRx receives NOA for anti-gluten toxicity polymer

|About: BioLineRx Ltd. (BLRX)|By:, SA News Editor

The USPTO issues a Notice of Allowance to BioLineRx (NASDAQ:BLRX) covering the use of its polymer, BL-7010, for the prevention or decreasing of gluten's deleterious side effects on the gastrointestinal mucosa. The patent, when issued, will be in effect until 2026.

BL-7010 is a non-absorbable orally available polymer intended for the treatment of celiac disease. It has a high affinity for gliadins, the immunogenic proteins in gluten that cause celiac disease. BL-7010 masks gliadins from enzymatic degradation which prevents the formation of immunogenic peptides that trigger the immune response. The immune response to gluten is thereby significantly reduced. BL-7010 is excreted via the bowel and not absorbed into the blood stream.